Background: Chronic heart failure (CHF) is a leading cause of both morbidity and mortality worldwide. The pathophysiologic understanding of chronic heart failure (CHF) has shifted from a mere hemodynamic disorder to a much more complex approach including changes and imbalances in neurohormonal, immune, and metabolic functions. Hyperuricemia is a constant finding in CHF. Aim: To estimate the level of uric acid (UA) in patients with CHF, and to determine the possible correlation with established prognostic markers in these patients. Patients and Methods: Ninety-five patients with CHF were studied. Detailed clinical assessment, ECG, laboratory investigations and echocardiography were performed for all patients. Serum UA level >7.0 mg/dl was determined high. Results: The age range of our patients was 28-85 years (median age 67). Of this group, 54 were male. The duration of the disease ranged from 113 years. In addition, 56% of patients were diabetic, 64% were hypertensive, and 74% had ischemic heart disease. Of our study group, 41 patients were class III New York Heart Association (NYHA) functional calcification, whereas 34 patients and 12 patients were in class II & IV respectively. The following diagnostic information was obtained: 1) blood pressure readings were 60 -123mmHg (mean=87.9±14.4). 2) atrial fibrillation (AF) was noted in 36 patients (38%) 3) left ventricular ejection fraction (EF %) was 13-68% (mean=37.9±20.1) 4) blood urea ranged from 13-197 mg/dl (mean=64.7±42.6) 5) serum creatinine was 0.4-5.5mg/dl (mean=1.4±0.9) 6) serum sodium was 119-148 (mean=134.2±5.9) 7) Elevated serum uric acid levels were found in 73% of our patients. We found a significant inverse correlation between serum uric acid level and mean arterial blood pressure (r = -0.42, p= 0.019). It is also noteworthy was left ventricular ejection fraction (EF%) (r= -0.31, p= 0.003). We also demonstrated a positive correlation between serum UA and blood urea (r= +0.21, p= .042), serum Cr (r= +0.21, p= 0.051) and age (r=+0.37, p= 0.034). The observed significant correlation between UA level and some established prognostic markers in these patients may indicate that serum UA could provide additional prognostic information in this population. We hypothesized that such a simple marker that can be measured anywhere at low cost which could identify high-risk patients with CHF.
Introduction
Chronic heart failure (CHF) is a leading cause of both morbidity and mortality worldwide, with increasing numbers in both prevalence and health care costs. Recently, our understanding has changed from a mere hemodynamic disorder to a much more complex approach, including neuroendocrine and immune activation. Not only is the cardiovascular system affected in the long-term course of heart failure, but peripheral tissues and organs contribute to both symptoms and progression of the disease. Current findings on metabolic imbalances and hormonal abnormalities occurring in CHF further contribute to the complex picture of this disease pathophysiology (1) .
Increasing body of evidence suggests that UA, a product of xanthine oxidase (XO), may be a useful marker for metabolic, hemodynamic, and functional staging in CHF and a valid predictor of survival in these patients. Recent data supports an expanded role for UA evaluation and the XO pathway in the pathogenesis of HF (2) . Moreover isolated hyperuricemia (irrespective of renal function and administration of drugs) appears to be a marker of altered oxidative metabolism, associated with tissue hypoxia. Uric acid levels reflect the degree of circulating XO activity characterized by elevation of levels of free radicals and inflammatory markers which could further damage cardiomyocytes and vascular endothelium. In addition, this can induce disturbances of myocardial contractility, vasoconstriction and may negatively affect the cardiovascular system and potentially worsen the prognosis in patients with CHF (3) (4) (5) (6) . Numerous population studies have previously reported that elevated UA levels are an independent predictor of cardiovascular mortality. Recent evidence suggests that lowering serum levels of UA may lead to improved outcomes in HF patients (7) (8) (9) (10) . The question of whether UA is only a marker rather than a causal factor in the pathogenesis of HF remains and will require futher evaluation.
We hypothesized that in CHF serum uric acid levels might be a simple, widely available and significant predictor of disease severity & could be added to the known prognostic indicators of this disease. The objective of our study was to estimate the level of uric acid (UA) in patients with CHF, and to determine the possible correlation with established prognostic markers in those patients.
Patients and methods
The study was conducted at The 7th October University Hospital and Benghazi Cardiac Center between July, 2009, and June, 2010. All patients recruited were diagnosed with CHF based on detailed history, clinical assessment, ECG, Chest X-ray & echocardiography evaluation of left ventricular ejection fraction (EF%) & LV diastolic function. Blood samples were collected from all patients & analyzed in standard methods for blood urea, serum creatinine and electrolytes. Serum uric acid level was measured, after overnight fasting by enzymatic methods using chemical analyzer. Hyperuricemia was defined as a serum UA level >7.0 mg/dl. The significant differences between serum uric acid levels in different patients' subgroups were tested by the parametric or non-parametric tests as appropriate. The correlation coefficients between serum UA and different prognostic markers were calculated using Pearson's correlation coefficient. Results were presented as percentage (%), range (median), range (mean ± 2SD) or correlation coefficient (r). Statistical significance was defined as P< 0.05.
Results
The age of patients ranged from 28 to 85 years; median age was 67 years. 54 patients were males. Disease duration ranged from 1 to 13 years. 56% of the patients had diabetes, 64% were hypertensive, 74% had ischemic heart disease, 60% had dyslipidemia, and 9.5% had chronic renal failure. It is noteworthy that 42 patients were in class III New York Heart Association (NYHA) functional calcification whereas 34 patients & 12 patients were in class II & IV respectively. Patients' mean blood pressure (MBP) was 60-123 mmHg (mean = 87.9±14.4), atrial fibrillation (AF) was found in 36 patients (38%). Left ventricular ejection fraction (EF %) range was 13-68% (37.9 ± 20.1). Blood urea range was 13-197mg/dl (64.7 ± 42.6), serum creatinine was 0.4-5.5mg/dl (1.4 ± 0.9), serum sodium was 119-148 (134.2 ± 5.9). Ninety three patients (98%) were on 
Discussion
In this study of Libyan patients with different functional stages of CHF, we demonstrated that 73% of these patients had elevated serum UA levels. On the other hand, a significant negative correlation between high UA levels to low blood pressure and low left ventricular ejection could indicate that UA levels in patients with CHF is correlated with the severity of the disease. Hence this could be a reliable prognostic marker. Increased UA levels have consistently been reported in patients with CHF, and recent clinical data supports the possibility that UA adds important prognostic information alone and in combination with other measures of cardiac function and patient functional status in this group (4) . Numerous studies have reported that hyperuricemia carries an increased relative risk of allcause mortality in patients with CHF, independent of other risk factors. In a recent meta-analysis of 1456 patients with HF, high UA levels increased all-cause mortality in patients with both acute and chronic HF (11) . Our findings are consistent with previous observations which found hyperuricemia was common in patients with HF. Higher uric acid level was independently associated with longterm adverse outcomes in these patients (12) .
Several studies have shown an association between increased serum UA levels in CHF and morbidity and mortality (13) (14) (15) . Data from the Beta-Blocker Evaluation of Survival Trial took a different approach (16) assuming that hyperuricemia without CRF is primarily due to increased production of uric acid from the failing heart. Their conclusion was that hyperuricemia is associated with poor outcome in CHF without CRF. This finding suggests that hyperuricemia in CHF without CRF might be linked to increased XO activity. Although, the role of XO in CHF is not clearly established, its relation to tissue hypoxia, circulating free radicals, inflammatory mediators, & endothelial & cardiomyocyte dysfunction could all have a negative effect on the cardiovascular system leading to poor outcomes in CHF patients (5) . Moreover, it appears that the inhibition of XO activity in patients with hyperuricaemia may have a beneficial effect on endothelial cell function, myocardial function and ejection fraction. Gotsman, et al found in a heart failure register-based study that treatment with allopurinol in CHF was associated with improved survival. (15) . Another retrospective study examined the effect of allopurinol on mortality and hospitalization in this patient population (17) . Long-term high-dose allopurinol (300 mg/d) was associated with a better all-cause mortality (adjusted relative risk 0.59; 95% confidence interval, 0.37-0.95; P=0.05).
In conclusion, hyperuricemia was observed in 73% of our patients with congestive heart failure. The significant correlation between the level of uric acid and low left ventricular ejection fraction in patients with established heart failure may indicated the important role of uric acid level as a prognostic marker. Regardless of whether UA levels are ready for routine clinical use, either as a prognostic factor or novel therapeutic target, further prospective studies are necessary to demonstrate that routine measurement or reduction of UA levels improves outcomes in HF patients.
